SAN ANTONIO--(EON: Enhanced Online News)--Results from three studies being presented at the 37th Annual
San Antonio Breast Cancer Symposium this week underscore the unique
abilities of bioTheranostics’
Breast
Cancer IndexSM molecular test, providing additional
strong evidence of both its predictive and prognostic power.

“Only about 3-5
percent of breast cancer patients in the United States benefit from
extended endocrine therapy—which is associated with significant side
effects and safety challenges”

According to Nicolas Barthelemy, president and CEO of bioTheranostics,
the findings add to the growing body of research establishing the Breast
Cancer Index as the “biomarker of endocrine response.” “Only about 3-5
percent of breast cancer patients in the United States benefit from
extended endocrine therapy—which is associated with significant side
effects and safety challenges,” Barthelemy said. “The Breast Cancer
Index is distinct in that it provides molecular information that
facilitates selection of women who are likely to benefit from continuing
endocrine treatment beyond five years, thus potentially sparing those
unlikely to benefit from adverse events and toxicities that can
negatively affect their health and quality of life.”

The first study compared the Breast Cancer Index (HoxB13/IL17BR) with
quantitative hormone receptor (ER and PR) expression and HER2 expression
in predicting benefit from adjuvant tamoxifen therapy in
estrogen-receptor positive (ER+) patients from the prospective,
randomized Stockholm trial. The analysis, which included 600 patients,
found that only the Breast Cancer Index (HoxB13/IL17BR) was predictive
of benefit from endocrine therapy. The poster presentation (No.
P3-06-06; Zhang Y, et al.), is titled “Prediction of Benefit from
Endocrine Therapy in ER+ Early Stage Breast Cancer: Correlative Studies
of the Breast Cancer Index HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2
Expression in the Randomized Stockholm Trial.”

A second study investigated the Breast Cancer Index in the landmark
TransATAC study, further demonstrating its prognostic strength in
patients with ER+, lymph node-negative breast cancer. In this study, the
Breast Cancer Index was a significantly better predictor of 10-year risk
of distant recurrence than tumor size or tumor grade, and integration of
tumor size and grade with the Breast Cancer Index did not improve the
ability to predict risk of recurrence in a clinically meaningful manner.
The poster presentation (No: P4-11-19; Sestak I, et al.) is titled
“Integration of Breast Cancer Index (BCI) with Clinicopathological
Factors for Prediction of Distant Recurrence in ER+ Breast Cancer.”

A third study evaluated the prognostic ability of the Breast Cancer
Index in lymph node-positive patients. In this study of 292 patients
from the NCIC CTG MA.14 trial, the Breast Cancer Index was a significant
predictor of risk of distant recurrence in node-positive patients. The
poster presentation (No. P6-01-10; Sgroi D, et al.), is titled
“Prognostic Significance of Breast Cancer Index (BCI) in Node-Positive
Hormone Receptor Positive Early Breast Cancer: NCIC CTG MA.14.”

About the Breast Cancer Index

The Breast Cancer Index is a unique molecular genomic test based on its
ability to inform decisions about extended endocrine treatment for ER+
breast cancer patients. It is the only test on the market that predicts
which patients have a high vs. low likelihood of benefitting from
extended endocrine therapy and quantifies the risk of late (>5 years
post-diagnosis) breast cancer recurrence. Development of the test stems
from more than 10 years of research and clinical validation designed to
investigate and discover biomarkers that track the multiple cellular
signaling pathways that can lead to endocrine response and breast cancer
recurrence. The result is a breakthrough test that helps oncologists and
patients navigate the difficult trade-off between wanting to take steps
to prevent recurrence of their disease and facing significant side
effects and safety challenges related to extended endocrine therapy.

About bioTheranostics

bioTheranostics,
Inc., is a leader in helping physicians improve the care and
management of cancer patients, offering a suite of proprietary molecular
diagnostic tests that allow treatment to be tailored to individual
patients. The company’s Breast
Cancer IndexSM helps oncologists make difficult decisions
about extended endocrine therapy for estrogen receptor-positive breast
cancer patients based on its unique ability to predict risk of late
disease recurrence and identify which patients are likely to benefit
from continuing therapy beyond five years. Its bioT3
Metastatic Cancer Solution combines accurate diagnosis with
comprehensive biomarker information that allows improved treatment for
metastatic cancer patients. bioTheranostics, a bioMérieux company, is
based in San Diego. For more information, visit www.biotheranostics.com
or www.AnswersBeyond5.com.
Follow us on Twitter @answersbyond5.

Note to editors: To request copies of the studies, contact Barbara
Sullivan at bsullivan@sullivanpr.com
or 714-374-6174.